Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | JANX008 |
Synonyms | |
Therapy Description |
JANX008 is a tumor-activated T cell engager (TRACTr) targeting EGFR and CD3, which potentially inhibits tumor growth (Cancer Immunol Res 2022;10(12 Suppl):Abstract nr B04). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
JANX008 | JANX-008|JANX 008 | CD3 Antibody 107 EGFR Antibody 64 | JANX008 is a tumor-activated T cell engager (TRACTr) targeting EGFR and CD3, which potentially inhibits tumor growth (Cancer Immunol Res 2022;10(12 Suppl):Abstract nr B04). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05783622 | Phase I | JANX008 | Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies | Recruiting | USA | 0 |